查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1923889

钼-99和Technetium-99m市场按应用、来源、产品类型和最终用户划分－2026年至2032年全球预测

Molybdenum-99 & Technetium-99m Market by Application, Source, Product Type, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，钼-99 和Technetium-99m 市场价值将达到 35.5 亿美元，到 2026 年将成长到 37 亿美元，到 2032 年将达到 55.1 亿美元，复合年增长率为 6.48%。

关键市场统计数据
基准年 2025 35.5亿美元
预计年份：2026年 37亿美元
预测年份 2032 55.1亿美元
复合年增长率 (%) 6.48%

权威概述将钼-99和Technetium-99m定位为现代诊断影像和临床工作流程中不可或缺且技术复杂的基础。

钼-99及其崩坏产物Technetium-99m是现代核医学的基石，它们支持多种诊断影像检查，并辅助特定的治疗方案。Technetium-99m具有优异的物理性质，例如半衰期短、伽马射线发射特性理想，使其特别适用于心臟病学、神经病学和肿瘤学中的单光子发射成像。同时，其母体核种钼-99是实现广泛临床应用的主要放射性核种来源。除了临床诊断之外，这些放射性核种在工业和研究领域也有广泛的应用。放射性示踪剂和成像剂可用于材料测试、製程优化以及新型放射性药物的研究。

技术创新、监管改革和供应链转型如何共同重塑诊断放射性核种的生产路径和临床工作流程

过去十年间，钼-99和Technetium-99m生态系统经历了许多变革，重塑了其生产、分销和临床应用模式。技术创新加速了替代生产途径的采用，例如直接迴旋加速器生产Technetium-99m以及低浓缩非裂变反应器方法，从而降低了对少数老旧研究核子反应炉的依赖，并提高了监管方面的认可度。同时，发生器技术也在不断发展，柱化学和凝胶配方的改进提高了洗脱效率，减少了铝渗透，简化了现场操作，并缩短了临床团队的设置时间。

评估2025年关税对诊断同位素供应链的采购、製造投资和临床连续性的系统性影响

美国将于2025年实施的关税对钼-99和Technetium-99m的全球供应链产生了多方面的影响，并对筹资策略、生产经济和临床营运产生了连锁反应。这些关税影响进口的生产材料、产生器组件和成品同位素产品，给依赖跨境供应关係的机构带来了即时的成本压力。为此，相关人员在加快采购多元化、优先发展国内生产路线以及重新谈判长期采购合约的步伐，以确保在更可预测的总到岸成本框架下供应的连续性。

透过深度細項分析，将临床应用、製造技术、产品形式和机构最终用户需求连结起来，从而指导可行的商业化策略。

细分市场层面的趋势分析揭示了不同应用、平台技术、产品形式和终端用户类别之间存在着不同的商业性和营运重点，这些重点都会影响投资规划和服务设计。在应用领域，诊断影像检查仍然是临床需求的主要来源，而心臟病学、神经病学和肿瘤学等亚专科的需求模式则影响着示踪剂的选择和检查安排。心臟病学检查通常需要可预测且频繁的示踪剂供应以支持负荷成像项目；神经病学工作流程需要具有特定成像窗口的示踪剂用于受体和灌注研究；肿瘤学应用则优先考虑能够实现病灶定位和分期的示踪剂，这导致对同位素新鲜度和发生器吞吐量的需求各不相同。工业应用需要不同的性能特征，强调放射化学稳定性和可追溯性，而治疗应用则对纯度和剂量有严格的限制，这会影响生产和品管流程。

区域比较分析突显了各主要区域在生产能力、法规环境和临床需求模式方面的差异，这些差异影响诊断同位素的供应。

区域趋势塑造生产选择、监管方式和供应链结构，进而直接影响供应可用性和临床应用。在美洲，强劲的临床需求、集中的科学研究基础设施以及注重提升国内韧性的政策，正推动对区域生产路径的投资。同时，医疗保健体系的多样性导致私立医院和公立医疗网络在筹资策略上存在显着差异。这种区域动态既支持大规模生产以促进跨境分销，也支持照护现场创新以缩短运往高需求临床中心的前置作业时间。

在诊断同位素生态系统中，竞争定位、技术研发和卓越的物流能力将决定哪些组织能够获得长期价值。

在钼-99和Technetium-99m产业生态系中，各公司之间的竞争主要围绕着技术差异化、供应可靠性以及製造、分销和临床支援服务的整合。领先企业优先投资于能够减少运输依赖的生产方式，例如加强区域迴旋加速器网路和发电机组装能力；而其他企业则致力于提高现有核子反应炉供应链的效率。製造商、物流供应商和临床网路之间的伙伴关係与策略联盟日益普遍，旨在确保交付时间并提供现场培训、品质保证和法规支援等附加价值服务。

为製造商、医疗服务提供者和政策制定者提供具体策略和操作指南，以确保可靠的同位素供应并加速临床应用。

产业领导者应采用组合式生产和采购策略，平衡集中式批量生产能力与分散式按需生产能力，以降低单点故障风险，并提高对临床计画的应对力。在需求量大的临床中心附近投资兴建迴旋加速器设施，将有助于缩短週转时间，实现当日手术；同时，维持发电机持续生产能力，可确保依赖多日洗脱策略的机构的运作连续性。企业应优先考虑模组化投资，以便逐步扩展，并透过遵循可预测的监管路径来加快产品上市速度。

我们采用严谨的多方法研究框架，结合关键相关人员对话、技术审查和供应链建模，以确保研究结果的可靠性和检验。

本分析的调查方法整合了一手和二手证据，并结合技术检验和相关人员三​​角测量，以确保获得可靠的实践见解。一手研究包括对行业相关人员相关者（包括生产工程师、放射性药物管理人员、采购负责人、法规事务专业人员和物流运营人员）进行结构化访谈和深入的定性讨论，以直接观察运营挑战和战略重点。二手研究包括对技术文献、监管指南、专利申请和行业期刊进行系统性回顾，以梳理技术和政策趋势。

摘要强调，协调一致的投资、清晰的监管政策和稳健的营运是实现永续诊断同位素取得的基础。

确保钼-99和Technetium-99m的稳定供应对现代诊断医学至关重要。技术创新、不断变化的法规以及供应链重组之间的协同作用，为价值链上的相关人员带来了机会和责任。替代生产技术和改进的发生器化学成分为供应多元化和降低系统风险提供了有希望的途径，但要实现这些益处，需要协调一致的投资、清晰的监管和卓越的运作。包括贸易措施和基础建设资金筹措在内的政策决策，对采购经济效益和投资奖励有着直接的影响。这凸显了采取综合方法的必要性，该方法既要兼顾产业政策，又要确保患者获得所需药物。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依应用分類的钼-99和Technetium-99m市场

  • 影像检查
    • 心臟病学
    • 神经病学
    • 肿瘤学
  • 工业应用
  • 治疗用途

9. 依来源分類的钼-99和Technetium-99m市场

  • 迴旋加速器
  • 核子反应炉

10. 依产品类型分類的钼-99和Technetium-99m市场

  • 散装钼 99
  • 直接生产
  • 发电机
    • 氧化铝柱
    • 凝胶发生器

11. 依最终用户分類的钼-99和Technetium-99m市场

  • 诊断检查室
    • 医院检查室
    • 独立检验机构
  • 医院
  • 研究所
    • 政府机构
    • 大学

12. 钼-99和Technetium-99m市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 按组别分類的钼-99和Technetium-99m市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国钼-99和Technetium-99m市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国钼-99和Technetium-99m市场

16. 中国钼-99和Technetium-99m市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • BWX Technologies, Inc.
  • Cardinal Health, Inc.
  • Curium US LLC
  • GE HealthCare Technologies Inc.
  • IRE NV
  • Jubilant DraxImage Inc.
  • Lantheus Medical Imaging, Inc.
  • Mallinckrodt Pharmaceuticals plc
  • NorthStar Medical Radioisotopes, LLC
  • NTP Radioisotopes SOC Ltd
  • SHINE Technologies, Inc.
  • Siemens Healthineers AG
Product Code: MRR-7A380DA7C318

The Molybdenum-99 & Technetium-99m Market was valued at USD 3.55 billion in 2025 and is projected to grow to USD 3.70 billion in 2026, with a CAGR of 6.48%, reaching USD 5.51 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.55 billion
Estimated Year [2026] USD 3.70 billion
Forecast Year [2032] USD 5.51 billion
CAGR (%) 6.48%

An authoritative overview framing molybdenum-99 and technetium-99m as essential, technically complex pillars of modern diagnostic imaging and clinical workflows

Molybdenum-99 and its decay product technetium-99m remain cornerstones of contemporary nuclear medicine, underpinning a vast swath of diagnostic imaging procedures and supporting certain therapeutic pathways. Technetium-99m's favorable physical properties, including its short half-life and ideal gamma emission, make it uniquely suited for single photon emission imaging across cardiology, neurology, and oncology, while the parent isotope molybdenum-99 serves as the primary source for distribution models that enable widespread clinical access. Beyond clinical diagnostics, these radionuclides find application in industrial settings and research contexts, where radiotracers and imaging agents support material testing, process optimization, and experimental investigations into new radiopharmaceuticals.

The production landscape for these isotopes is technically complex and capital-intensive, spanning reactor-based fission routes and accelerator or cyclotron pathways that directly produce technetium-99m or precursor isotopes. The downstream ecosystem encompasses bulk isotope suppliers, generator manufacturers that convert molybdenum-99 into clinically usable technetium-99m, and a network of diagnostic laboratories, hospitals, and research institutions that manage cold-chain logistics and clinical administration. Regulatory oversight at national and international levels governs radiological safety, transport, and clinical use, while quality management systems ensure consistent specific activity, purity, and sterility of radiopharmaceutical products.

This report synthesizes technical, regulatory, and supply chain considerations to inform strategic choices by manufacturers, healthcare providers, and policymakers. It examines production technologies, generator designs, clinical utilization patterns across major diagnostic specialties, and evolving supply chain risks and mitigations. The analysis highlights where investment, policy alignment, and operational innovation can reduce systemic fragility and support resilient access to critical diagnostic isotopes.

How technological, regulatory, and supply chain innovations have together reshaped production pathways and clinical workflows for diagnostic radionuclides

Over the past decade the molybdenum-99 and technetium-99m ecosystem has experienced several transformative shifts that reshape production, distribution, and clinical usage patterns. Technological innovation has accelerated the adoption of alternative production pathways, including direct cyclotron production of technetium-99m and low-enrichment or non-fission reactor approaches, which reduce reliance on a small set of aging research reactors and improve regulatory acceptability. Concurrently, generator technology has evolved with refinements in column chemistry and gel formulations that aim to enhance elution efficiency, reduce aluminium breakthrough, and simplify on-site handling, thereby shortening preparation timelines for clinical teams.

Supply chain resilience has become a strategic priority for healthcare systems and governments alike, prompting investments in domestic capacity, redundancy across sources, and improvements in cold-chain logistics. Regulatory frameworks have responded by streamlining pathways for alternative production technologies while reinforcing quality and safety requirements, creating clearer pathways for commercialization but also imposing rigorous validation standards. Clinical practice has adapted to these technical and regulatory changes, with nuclear medicine departments optimizing scheduling, radiopharmacy throughput, and tracer selection to align with variable delivery windows and generator performance.

Finally, the broader healthcare and policy landscape has elevated the strategic significance of secure isotope supply as a component of national health resilience. This change has translated into novel funding models, public-private partnerships, and cross-sector collaborations that link industrial capability with clinical demand. The cumulative effect of these trends is a more diversified technology base and a heightened focus on interoperability between producers, distributor networks, and clinical end users, which together underpin a more adaptive and technology-driven supply model for diagnostic radionuclides.

Assessing the systemic effects of 2025 tariff measures on procurement, manufacturing investment, and clinical continuity in the diagnostic isotope supply chain

United States tariff measures introduced in 2025 have exerted a multifaceted influence on the global supply chain for molybdenum-99 and technetium-99m, with implications that ripple across procurement strategies, manufacturing economics, and clinical operations. Tariffs that affect imported production inputs, generator components, and finished isotope consignments create immediate cost pressures for organizations that rely on cross-border supply relationships. In response, stakeholders have accelerated efforts to diversify sourcing, prioritize domestic production pathways, and renegotiate long-term procurement contracts to secure continuity of supply under more predictable total landed cost frameworks.

Tariff impacts extend beyond direct cost increases; they influence investment calculus for both incumbent producers and potential entrants. Higher import duties on critical components for generators, column materials, or specialized transport packaging can lengthen payback periods for new manufacturing facilities and may shift capital toward locally producible technologies such as cyclotron systems and generator assembly lines. This reallocation of capital has the potential to catalyze regional manufacturing clusters that reduce cross-border dependencies, yet it also introduces timing mismatches as new capacity requires regulatory approvals and workforce training before it can alleviate short-term supply constraints.

Clinically, tariff-driven cost dynamics can translate into tighter operating margins for hospital radiopharmacies and independent diagnostic laboratories, prompting workflow adaptations that prioritize high-value procedures and optimize tracer utilization. Procurement teams increasingly evaluate total cost of ownership, factoring in tariff exposure, logistics complexity, and supplier redundancy when structuring contracts. On a policy level, tariffs have prompted dialog between public health authorities and trade negotiators to balance industrial policy objectives with the imperative of uninterrupted access to essential medical isotopes. In parallel, industry consortia and supply chain partners have intensified collaboration to streamline certificate of origin documentation, harmonize customs procedures, and leverage bonded logistics solutions to mitigate tariff impacts.

Overall, the 2025 tariff environment functions as a catalyst for supply chain reconfiguration: it accelerates localization trends, sharpens focus on technology choices that reduce import intensity, and compels healthcare buyers to adopt more sophisticated procurement strategies that integrate tariff risk into resilience planning. While tariffs can impose short-term friction, they also incentivize investments that, if well coordinated, may strengthen long-term supply stability and align production capacity more closely with national clinical needs.

Deep segmentation analysis linking clinical applications, production technologies, product formats, and institutional end-user needs to actionable commercialization strategies

Segment-level dynamics reveal distinct commercial and operational priorities across applications, source technologies, product forms, and end-user categories, each with implications for investment and service design. In terms of application, diagnostic imaging remains the dominant clinical driver with sub-specialty demand patterns in cardiology, neurology, and oncology shaping tracer selection and scheduling practices; cardiology procedures often demand predictable, high-frequency deliveries to support stress imaging programs, neurology workflows require tracers with specific imaging windows for receptor and perfusion studies, and oncology applications prioritize agents that enable lesion localization and staging, creating divergent requirements for isotope freshness and generator throughput. Industrial applications demand different performance characteristics, emphasizing radiochemical robustness and traceability, while therapeutic applications impose rigorous purity and dosing constraints that influence production and quality control processes.

When viewed by source, the industry bifurcates between cyclotron and reactor pathways, with cyclotron approaches offering geographically distributed, on-demand production that reduces transport time and radiological decay losses, and reactor-based production providing high-volume bulk quantities that feed generator supply chains. Each source route influences logistics and regulatory strategy: cyclotron facilities necessitate local technical expertise and maintenance ecosystems, while reactor-sourced supply depends on long-range transport, packaging regulations, and international collaboration.

Product type segmentation further differentiates market behavior. Bulk molybdenum-99 serves as the feedstock for traditional generator models and is subject to long-lead manufacturing and transport considerations. Direct production methods that bypass molybdenum intermediates alter the downstream value chain by enabling point-of-care technetium supply but require different regulatory dossiers and local infrastructure. Generator products themselves are subdivided by chemistry and form factor; alumina column designs represent a long-standing, widely deployed approach with predictable elution profiles, whereas gel generators present opportunities for simplified handling and potential improvements in elution efficiency, each demanding distinct manufacturing controls and user training.

End-user segmentation emphasizes how clinical and institutional structures shape demand and procurement. Diagnostic laboratories-whether hospital based or independent-operate on tight timelines and must balance throughput with regulatory compliance and staff competencies. Hospitals, split between private and public models, exhibit different budgetary constraints and procurement cycles that affect their willingness to invest in on-site cyclotrons or multi-day generator strategies. Research institutes, whether government laboratories or universities, often prioritize experimental flexibility and trace isotope types for development work, necessitating bespoke sourcing arrangements and collaborative agreements with producers. Understanding these intersecting segmentation axes is critical for manufacturers and service providers designing product portfolios, commercial terms, and support services that align with end-user capabilities and clinical workflows.

Comparative regional analysis revealing how production capacity, regulatory environments, and clinical demand patterns shape secured access to diagnostic isotopes across major world regions

Regional dynamics shape production choices, regulatory approaches, and supply chain architectures in ways that directly affect availability and clinical adoption. In the Americas, strong clinical demand, concentrated research infrastructure, and policy interest in domestic resilience have driven investments in localized production pathways, while diverse healthcare systems mean procurement strategies vary significantly between private hospitals and public health networks. This regional profile supports both large-scale production that feeds cross-border distribution and point-of-care innovations that reduce transport lead times for high-volume clinical centers.

Europe, Middle East & Africa presents a mosaic of regulatory frameworks and production capabilities. Several nations within this region have longstanding reactor capacity alongside emerging accelerator initiatives, creating a hybrid supply matrix. Regulatory harmonization efforts in parts of the region aim to simplify cross-border distribution and mutual recognition of quality standards, yet logistical complexity and variable infrastructure across countries necessitate tailored distribution and contingency planning. In some jurisdictions, strategic stockholding and intergovernmental agreements have been deployed to buffer short-term disruptions and ensure continued access for high-priority clinical services.

Asia-Pacific demonstrates rapid adoption of alternative production technologies and ambitious expansion of cyclotron networks to meet dense urban demand centers. Robust manufacturing ecosystems for medical devices and radiopharmacy components support local production scaling, while policy focus on domestic industrial capability encourages public-sector investment in isotope infrastructure. Clinical adoption patterns in the region often emphasize procedural volume and throughput optimization, making reliable, frequent deliveries and efficient generator solutions particularly valuable. Across all regions, differences in regulatory timelines, transport logistics, and financing models drive variation in how producers and healthcare providers approach strategic investment and operational design.

How competitive positioning, technological R&D, and logistics excellence determine which organizations capture long-term value in the diagnostic isotope ecosystem

Competitive dynamics among firms operating in the molybdenum-99 and technetium-99m ecosystem revolve around technological differentiation, supply reliability, and the integration of manufacturing with distribution and clinical support services. Leading organizations prioritize investments in production modalities that lower transport dependencies, such as regional cyclotron networks and enhanced generator assembly capabilities, while others pursue efficiency gains within existing reactor-based supply chains. Partnerships and strategic alliances between manufacturers, logistics providers, and clinical networks are increasingly common as companies seek to guarantee delivery windows and provide value-added services such as on-site training, quality assurance, and regulatory support.

R&D intensity centers on generator chemistry improvements and production process optimization that can reduce waste, shorten preparation times, and improve elution yields. Firms that invest in advanced quality management and digital traceability systems are better positioned to meet stringent regulatory expectations and customer demands for transparency. Commercial strategies reflect a dual imperative: secure long-term supply contracts with large hospital systems and establish flexible offerings for smaller diagnostic laboratories that require just-in-time deliveries. This bifurcated approach supports revenue stability while enabling penetration into emerging markets where on-demand production models may be more commercially attractive.

Operational excellence in logistics and cold chain management remains a critical differentiator. Companies that achieve high fulfillment reliability through robust packaging, customs expertise, and contingency routing create tangible clinical value by minimizing procedure cancellations and improving scheduling predictability. As capital flows to new production capacity and generator innovation, the ability to navigate regulatory approvals, scale manufacturing, and sustain quality at volume will determine which firms capture long-term adoption across clinical and research segments.

Actionable strategic and operational directives for manufacturers, healthcare providers, and policymakers to secure reliable isotope supply and accelerate clinical adoption

Industry leaders should adopt a portfolio approach to production and sourcing that balances centralized bulk capacity with decentralized, on-demand capabilities to reduce single-point vulnerabilities and improve responsiveness to clinical schedules. Investing in cyclotron capacity in proximity to high-volume clinical centers will shorten delivery windows and support same-day procedures, while continued stewardship of generator manufacturing capabilities ensures continuity for facilities that rely on multi-day elution strategies. Firms should prioritize modular investments that can be scaled incrementally and that align with foreseeable regulatory pathways to accelerate time-to-market.

Strengthening relationships with regulatory authorities and participating in harmonization initiatives can accelerate approvals for alternative production technologies and new generator chemistries. Proactive engagement reduces uncertainty and enables companies to shape standards that balance innovation with patient safety. At the procurement level, healthcare providers should integrate tariff risk and supply chain resilience into contracting strategies, favoring agreements that include redundancy provisions, flexible delivery terms, and performance guarantees. Cross-sector collaboration, including public-private partnerships, can mobilize funding for critical infrastructure while aligning public health objectives with commercial incentives.

Operationally, organizations must elevate quality assurance, workforce training, and digital traceability. Investing in training programs for radiopharmacy technicians and logistics personnel mitigates risks associated with new generator types and on-site production equipment. Implementing end-to-end digital tracking for batch identity, temperature control, and chain-of-custody increases transparency and supports rapid incident response. Finally, sustainability and environmental compliance should inform capital projects and operational upgrades, as responsible waste management and energy efficiency create social license and reduce long-term operational costs.

A rigorous, multi-method research framework combining primary stakeholder engagement, technical review, and supply chain modeling to ensure reliable, verifiable insights

The research methodology underpinning this analysis integrates primary and secondary evidence with technical validation and stakeholder triangulation to ensure robust, actionable findings. Primary research comprised structured interviews and deeper qualitative discussions with a cross-section of industry participants, including production engineers, radiopharmacy managers, procurement officers, regulatory affairs specialists, and logistics providers, enabling direct observation of operational challenges and strategic priorities. Secondary research involved a systematic review of technical literature, regulatory guidance, patent filings, and trade publications to map technology trajectories and policy developments.

Supply chain mapping and process modeling were employed to assess points of fragility, lead times, and capital intensity across production routes, while scenario analysis evaluated the operational implications of tariff changes, regulatory shifts, and technology adoption. Data quality assurance included cross-validation of interview insights with documentary evidence and anonymized case examples, ensuring that conclusions reflect operational realities rather than isolated perspectives. Limitations of the methodology are acknowledged: proprietary contract terms and non-public production schedules constrain visibility into some supplier behaviors, and rapidly evolving policy environments may alter timelines for infrastructure deployment. To mitigate these constraints, the study emphasizes principles, operational levers, and risk management strategies that remain applicable across differing market circumstances.

Finally, the analysis adheres to ethical research standards with confidentiality protections for interview participants and transparent documentation of sources and assumptions, enabling confidence in the reproducibility and integrity of the findings.

Concluding synthesis emphasizing coordinated investment, regulatory clarity, and operational resilience as the pillars of sustainable diagnostic isotope access

Securing consistent access to molybdenum-99 and technetium-99m is essential for contemporary diagnostic medicine, and the confluence of technological innovation, regulatory evolution, and supply chain realignment offers both opportunities and responsibilities for stakeholders across the value chain. Alternative production technologies and generator chemistry improvements provide credible pathways to decentralize supply and reduce systemic risk, but realizing these benefits requires coordinated investment, regulatory clarity, and operational excellence. Policy decisions, including trade measures and infrastructure funding, have immediate practical consequences for procurement economics and investment incentives, underscoring the need for integrated approaches that balance industrial policy with patient access imperatives.

For manufacturers, the dual focus on technology differentiation and logistical reliability will determine commercial success, while healthcare providers must adapt procurement and clinical workflows to leverage new delivery models. Regulators and policymakers play a critical role in shaping standards that preserve safety while encouraging innovation. In this context, strategic collaboration-whether through public-private partnerships, inter-institutional agreements, or industry consortia-represents the most effective route to build resilient, efficient, and clinically responsive isotope supply systems.

The trajectory ahead is defined by pragmatic choices: prioritize redundancy where risk is intolerable, invest in local capability where clinical demand justifies it, and pursue incremental innovation that reduces handling complexity and enhances clinical value. Stakeholders that act decisively and cooperatively will strengthen the reliability of diagnostic services and support better patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Molybdenum-99 & Technetium-99m Market, by Application

  • 8.1. Diagnostic Imaging
    • 8.1.1. Cardiology
    • 8.1.2. Neurology
    • 8.1.3. Oncology
  • 8.2. Industrial Applications
  • 8.3. Therapeutics

9. Molybdenum-99 & Technetium-99m Market, by Source

  • 9.1. Cyclotron
  • 9.2. Reactor

10. Molybdenum-99 & Technetium-99m Market, by Product Type

  • 10.1. Bulk Molybdenum 99
  • 10.2. Direct Production
  • 10.3. Generator
    • 10.3.1. Alumina Column
    • 10.3.2. Gel Generator

11. Molybdenum-99 & Technetium-99m Market, by End User

  • 11.1. Diagnostic Laboratory
    • 11.1.1. Hospital Based Laboratory
    • 11.1.2. Independent Laboratory
  • 11.2. Hospital
  • 11.3. Research Institute
    • 11.3.1. Government Institute
    • 11.3.2. University

12. Molybdenum-99 & Technetium-99m Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Molybdenum-99 & Technetium-99m Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Molybdenum-99 & Technetium-99m Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Molybdenum-99 & Technetium-99m Market

16. China Molybdenum-99 & Technetium-99m Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. BWX Technologies, Inc.
  • 17.6. Cardinal Health, Inc.
  • 17.7. Curium US LLC
  • 17.8. GE HealthCare Technologies Inc.
  • 17.9. IRE NV
  • 17.10. Jubilant DraxImage Inc.
  • 17.11. Lantheus Medical Imaging, Inc.
  • 17.12. Mallinckrodt Pharmaceuticals plc
  • 17.13. NorthStar Medical Radioisotopes, LLC
  • 17.14. NTP Radioisotopes SOC Ltd
  • 17.15. SHINE Technologies, Inc.
  • 17.16. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CARDIOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CARDIOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDUSTRIAL APPLICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDUSTRIAL APPLICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDUSTRIAL APPLICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY THERAPEUTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY THERAPEUTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CYCLOTRON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CYCLOTRON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY CYCLOTRON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY REACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY REACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY REACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY BULK MOLYBDENUM 99, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY BULK MOLYBDENUM 99, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY BULK MOLYBDENUM 99, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIRECT PRODUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIRECT PRODUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIRECT PRODUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ALUMINA COLUMN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ALUMINA COLUMN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY ALUMINA COLUMN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GEL GENERATOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GEL GENERATOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GEL GENERATOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL BASED LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL BASED LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL BASED LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDEPENDENT LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDEPENDENT LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY INDEPENDENT LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GOVERNMENT INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GOVERNMENT INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GOVERNMENT INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY UNIVERSITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY UNIVERSITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY UNIVERSITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 156. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 159. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 160. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 161. GCC MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 180. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 183. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 186. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 188. G7 MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 189. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 192. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 195. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 196. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 197. NATO MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY GENERATOR, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY DIAGNOSTIC LABORATORY, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA MOLYBDENUM-99 & TECHNETIUM-99M MARKET SIZE, BY RESEARCH INSTITUTE, 2018-2032 (USD MILLION)